Bluebird bio is lifting its voluntary marketing suspension in the EU for its β-thalassemia gene therapy, Zynteglo (betibeglogene autotemcel), after the European Medicines Agency said its drug safety committee had found no evidence that the treatment can cause acute myeloid leukemia (AML).
The safety committee, the PRAC, started reviewing Zynteglo in February, after two cases of AML were found in patients who...




